Revance Therapeutics Inc Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection Call Transcript
Good morning, and welcome to the Revance conference call. (Operator Instructions)
As a reminder, this call is being recorded today, September 8, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.
Thank you, Olivia. Good morning, everyone, and thank you for joining our conference call to discuss the U.S. FDA approval of DAXXIFY, a brand name for daxibotulinumtoxinA-lanm injection. Joining us are Chief Executive Officer, Mark Foley; President, Dustin Sjuts and Chief Financial Officer, Tobin Schilke.
The press release announcement and approval issued earlier today is available on our corporate website and contains the indication statement for DAXXIFY as well as important safety information. The product label and full U.S. prescribing information for DAXXIFY are also available on our website.
During this conference call, management will make forward-looking statements, including
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |